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Primary Immune Regulatory Disorders (PIRD) are an expanding group of diseases
caused by gene defects in several different immune pathways, such as regulatory
T cell function. Patients with PIRD develop clinical manifestations associated with
diminished and exaggerated immune responses. Management of these patients is
complicated; oftentimes immunosuppressive therapies are insufficient, and patients
may require hematopoietic cell transplant (HCT) for treatment. Analysis of HCT data in
PIRD patients have previously focused on a single gene defect. This study surveyed
transplanted patients with a phenotypic clinical picture consistent with PIRD treated in 33
Primary Immune Deficiency Treatment Consortium centers and European centers. Our
data showed that PIRD patients often had immunodeficient and autoimmune features
affecting multiple organ systems. Transplantation resulted in resolution of disease
manifestations in more than half of the patients with an overall 5-years survival of 67%.
This study, the first to encompass disorders across the PIRD spectrum, highlights the
need for further research in PIRD management.
Keywords: primary immune deficiencies, autoimmunity, immune dysregulation, hematopoietic cell transplant,
genetics
INTRODUCTION
The traditional classification of Primary Immune DeficiencyQ6
Q15 Disorders (PIDD) has consisted largely of patients who
present with recurrent, severe, or unusual infections due to
defects in immune effector mechanisms. However, a growing
proportion of the 344 gene defects now associated with primary
disorders of the immune system (1) do not have dominant
features of infection; rather, the predominant presentation
is with immune-mediated pathology including autoimmunity,
autoinflammation, or non-malignant lymphoproliferation. To
differentiate this group of disorders from traditional PIDD,
we propose that they be called collectively, Primary Immune
Regulatory Disorders or “PIRD.” An example prototypic
PIRD is IPEX (Immune Dysregulation, Polyendocrinopathy,
Enteropathy, and X-linked) syndrome since the principal
clinical feature is autoimmune in nature, including autoimmune
enteropathy, type I diabetes, autoimmune cytopenias, and
immune-mediated dermatitis (2, 3). Patients may also have
infections, but these are typically a less prominent feature of the
disease. Other disease groups that could reasonably be considered
in the PIRD category include Autoimmune Lymphoproliferative
Syndrome (ALPS), autoinflammatory disorders such as Familial
Mediterranean Fever (FMF), interferonopathies, and Common
Variable Immunodeficiency (CVID)-like disease in which
patients have hypogammaglobulinemia but autoimmune or
inflammatory features dominate their clinical presentation.
Management of PIRD patients is challenging and complex
given the frequent need for immunosuppressive therapies that
is often in the setting of a co-existing increased infectious
disease risk (4). Steroids are often used as an initial therapy
but have serious long-term complications. Targeted immune
therapies, such as cytokine or small molecule inhibitors, are
increasingly available with the advantage of fewer global immune
suppressive effects. However, patients with PIRD often do
not have an adequate clinical response to immunosuppressive
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treatment, resulting in referral for allogeneic hematopoietic cell
transplantation (HCT) as a potentially curative therapy. To date,
there has been limited data on the effectiveness of HCT for the
PIRD cohort as a whole. Given the increasing recognition of
PIRD cases, we surveyed transplant centers affiliated with the
Primary Immune Deficiency Treatment Consortium (PIDTC) in
the US and Canada as well as European centers to assemble data
from PIRD patients with and without known genetic defects, who
have undergone HCT at these sites.
METHODS
Q8
A survey was developed by a committee of immunologists,
rheumatologists, and blood and marrow transplant specialists
who care for patients with PIRD (Supplementary Table 1).
The survey was sent via email to all PIDTC sites (n = 44,
https://www.rarediseasesnetwork.org/cms/pidtc/Learn-More/
Participating-Clinical-Centers) (5) and three HCT referral
centers in Europe to determine the number and characteristics
of PIRD patients treated by HCT at each center. The majority
of centers (81%, 33 PIDTC and 3 European sites) responded
to the survey. Non-responding centers were contacted at least
three times by follow-up emails and/or phone calls. Survey
data were collected from January 2017 to October 2017. For
the purposes of this survey, a definition of “PIRD” was not
provided. Instead, centers were asked to report any patient that
had been transplanted specifically to treat clinical features of
“immune dysregulation.” Examples and disease categories were
provided such as CTLA4, IPEX, rheumatologic disorders, and
inflammatory bowel disease. For each patient, the following
information was requested: working diagnosis, genetic defect
(if known), clinical manifestations, HCT indication, HCT
conditioning regimen, donor and hematopoietic cell source, and
outcomes following HCT. Clinical manifestations were requested
based on categories and the center provided their impression
of whether an individual patient had each manifestation. For
the analysis, patients were grouped based on gene defects with
similar immune mechanisms or by the clinical manifestations.
Patients with HLH or genetic defects associated with familial
HLH were excluded, as these patients make up a unique group of
immune regulatory disorders that are being studied separately.
Statistical analysis was performed using Statistical Analysis
Software (SAS) v9.4.
RESULTS
The survey identified 226 patients with PIRD who received
HCT between 1982 and 2017 (median year 2011) from 30
PIDTC centers in North America and 3 European HCT centers.
Within the cohort, 76% (n = 171) had an immune-related gene
defect identified in one of 31 genes (Table 1). The remaining
patients had clinical features of PIRD, resembling those with
known genetic defects, but lacked an identified mutation or had
not undergone genetic testing. Patients were grouped into 11
categories based on common clinical features or shared genetic
immune pathway defects (Table 1). The majority of patients with
TABLE 1 | Disease groups with associated genes or pathways. Q5
Group Genes/Pathways # of HCT Patients (% of Total)
APDS PIK3CD 20 (8.8%)
PIK3R1 3 (1.3%)
Autoimmunity C1Q 3 (1.3%)
Unknown gene 11 (4.9%)
Autoinflammatory ADA2 2 (0.9%)
MVK 1 (0.4%)
PSTPIP1 1 (0.4%)
CID CD40L 3 (1.3%)
DOCK8 2 (0.9%)
MALT1 1 (0.4%)
RAG1 1 (0.4%)
ZAP70 3 (1.3%)
Unknown gene 6 (2.7%)
CVID TNFRSF13B (TACI) 1 (0.4%)
Unknown 31 (13.7%)
IBD IL10R 7 (3.1%)
Unknown gene 1 (0.4%)
Innate CD18 1 (0.4%)
IFNGR 1 (0.4%)
LAD 2 (0.9%)
STAT1-GOF 3 (1.3%)
TLR3 and STAT1-LOF 1 (0.4%)
LPD-Like ITK 1 (0.4%)
SAP 1 (0.4%)
XIAP 1 (0.4%)
Unknown gene 1 (0.4%)
NFKB IKBKB-LOF 4 (1.8%)
IKBKG 10 (4.4%)
NFKBIA 2 (0.9%)
Other 1 (0.4%)
Tregopathies CTLA4 13 (5.8%)
FOXP3 62 (27.4%)
IL2RA (CD25) 1 (0.4%)
LRBA 4 (1.8%)
STAT3-GOF 12 (5.3%)
Unknown gene 5 (2.2%)
Other* TCF4 1 (0.4%)
TTC7A 2 (0.9%)
*This group included genes that were associated with syndromic manifestations.
APDS, activated PI3K delta syndrome; CID, combined immune deficiency; CVID, common
variable immunodeficiency; GOF, gain of function; IBD, inflammatory bowel disease,
Innate, disorders of innate immunity; LOF, loss of function; LPD, lymphoproliferative
disorder, NFKB, nuclear factor kappa-light-chain-enhancer of activated B cells;
Tregopathies, T regulatory cell disorders.
an unknown genetic cause were in the CVID group. It is possible
that some of these patients would have been found to have genetic
defects if current genetic testing approaches had been available at
the time of their HCT.
Overall, patients with PIRD had a mean age of disease
onset of 2 years (median < 1 year, range 0–20 years) with
51% of patients presenting at <1 year of age. As anticipated,
individuals with PIRD had clinical manifestations indicative of
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overactive immunity (i.e., autoimmunity, autoinflammation,
lymphoproliferation) co-existing with impaired immune
function (i.e., immunodeficiency) (Figure 1A). Virtually all
organ systems were affected by immune-mediated pathology, but
the gastrointestinal (GI) system was most commonly involved,
with 72% of patients reported to have GI symptoms (Figure 1A).
Among patients with GI symptoms, enteropathy was the most
common GI manifestation (63%) followed by hepatitis (12%).
A large proportion of patients had failure to thrive (67%) likely
related to GI involvement. Autoimmune cytopenias (51%) were
also common in PIRD patients with 16% having hemolytic
anemia, 10% having immune-mediated thrombocytopenia,
and 21% having Evans syndrome. Skin involvement was also
prominent (55%) with the majority of these patients having
IPEX or gene defects in the NFkB signaling pathway. Organs less
involved in PIRD patients included brain, endocrine organs, and
musculoskeletal system.
Within each phenotypic disease group, the clinical
manifestations were more variable (Figure 1B). Hematologic
manifestations including autoimmune cytopenias, occurred
most commonly in subjects having APDS (activated PI3K delta
syndrome), CVID, T regulatory cell disorders (Tregopathies),
and autoinflammatory gene disorders. Lymphoproliferation was
also commonly seen in these groups. Organ specific immune
dysregulation also varied by group. Lung disease occurred
most frequently in subjects in the APDS, autoinflammatory
genes, and CVID groups, while endocrinopathies occurred
most frequently in Tregopathies and innate disease categories.
Immunodeficiency and infections occurred in >65% of
patients in all disease categories except for the autoimmunity
and inflammatory bowel disease groups. Autoinflammatory
manifestations were not commonly reported in the different
disease groups except in known autoinflammatory gene disorders
and the “other” category.
All patients (n = 226) included in the survey underwent
allogeneic HCT to manage PIRD features. The primary
indication for transplant was autoimmune manifestations (41%),
followed by immunodeficiency (26%), autoinflammation (8%),
lymphoproliferative disease (1%), and malignancy (1%). Twenty-
two percent of patients had multiple indications for transplant.
The median age at HCT was 7 years (range < 1–64 years).
Approximately one quarter (24%) underwent HCT prior to
1 year of age and 87% underwent HCT before age 18. The
time between the onset of symptoms and transplant ranged
from 0 to 58 years with a median of 5 years. The donor
source was predominantly bone marrow (65%), followed by
peripheral blood stem cells (20%), and umbilical cord blood
(14%). Human Leukocyte Antigen (HLA)-matched related
donors were utilized in 22% of cases, but the majority received
grafts from HLA-matched unrelated donors (53%). Mismatched
unrelated donors were used in 18% of cases, haploidentical
donors in 4%, and more than 2 donors were needed in 1%
of cases (n = 3). Conditioning regimens were characterized
by the reporting centers as myeloablative (39%, n = 87),
reduced intensity (36%, n= 82), or minimal intensity (8%,
n= 18). Conditioning intensity was not reported in 17% of
cases (n= 39).
FIGURE 1 | Clinical Manifestations of PIRD Patients. (A) PIRD patients have a Q4
Q5range of clinical manifestations. Hatched bars represent the type of immune
dysregulation [i.e., overactive immune features (autoimmunity,
autoinflammation, lymphoproliferation) or underactive immune features
(immunodeficiency)] and solid bars represent organ involvement. (B) Heat map
of the clinical manifestations (rows) in the disease groups (columns). Color
indicates the percentage of patients within that disease group that have the
particular clinical manifestation. Right bar represents the color scaling. APDS,
activated PI3K delta syndrome; CID, combined immunodeficiency; CVID,
common variable immunodeficiency; IBD, inflammatory bowel disease; Innate,
disorders of innate immunity; LPD, lymphoproliferative disorder; NFKB, nuclear
factor kappa-light-chain-enhancer of activated B cells; Tregopathies, T
regulatory cell disorders.
More than half (55%) of the patients had resolution of their
clinical manifestations after HCT (n = 125). Interestingly, all
patients in the IBD disease group had complete resolution
of their symptoms. Most disease groups had substantial
symptom resolution following HCT except for those with
NFκB defects where <50% of patients had improvement
(Figure 2A). The overall probability of survival at 5-years based
on Kaplan-Meier estimate is 67% (95% CI 59–74%) (Figure 2B).
Univariate or multivariate analysis suggested, though not
reaching statistical significance, that age of disease onset >5
years, being older than 5 years of age at HCT, or undergoing
HCT before 2000 were associated with increased mortality.
The most commonly reported causes of death were infection
(30%), multifactorial causes (18%), and graft vs. host disease
(GVHD) (12%).
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FIGURE 2 | HCT Outcomes in patients with PIRD. (A) Bar graph illustrating the resolution of disease at any point post-HCT in each of the disease groups based on
percentages within the group. Numbers represent patients in each subgroup. (B) Kaplan-Meier estimate of survival in PIRD patients undergoing HCT. Dotted lines
represent 95% confidence interval.
DISCUSSION
The is the first study that has collectively reported on HCT for
the expanding group of PIRD across a broad sample of treatment
centers. The purpose of the study was to summarize recent
use of HCT to treat PIRD of all underlying causes in centers
specializing in PIDD throughout the US, Canada and selected
European centers of excellence. The results suggest that a large
proportion of these rare diseases have required HCT and provide
preliminary overview of HCT outcomes. While previous reports
of HCT survival in selected PIRD genotypes have ranged from 40
to 80%, this is the first attempt to gain a broader overview of HCT
outcomes for clinical features of “immune dysregulation” (2, 3, 6–
16). For this reason, the study was intentionally broad in scope
and captured only a limited data set of key clinical features and
outcomes from these patients. The depth of information gathered
limited our ability to perform in-depth analyses of specific clinical
manifestations and HCT regimens. This is the first study that has
collectively reported on HCT for the expanding group of PIRD
disorders across a broad sample of treatment centers.
This study highlights the clinical manifestations that
prompted a consideration of HCT in patients with a suspected
PIRD disorder. Among these, severe GI disease was the most
common, but this may reflect the fact that patients with IPEX
made up the largest single group of patients reported by centers
(62/226, 27%). The study illustrates that HCT can be effective
for patients with PIRD; resolution of disease symptoms occurred
in at least a portion of the patients across most disease groups,
but overall long-term survival remained poor (67% at 5-years)
with a large portion of deaths occurring in the first 2 years
of life. The survival found in this cohort is similar to that
recently published for HCT in a broad spectrum of autoimmune
and autoinflammatory diseases from European centers (70%
at 5-years) (17). Both studies gathered retrospective data
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spanning a broad timeframe where there has been significant
advances in conditioning regimen, targeted immune modulatory
therapies for GVHD, and supportive care. It is possible with
current advances in HCT practices that transplantation may
be a more optimal therapy to consider earlier in the disease
course. Therefore, significant work is needed to identify the
types of patients that would benefit most from HCT, to better
understand the factors that lead to death after transplant,
and to discern potential modifications that could be made to
treatment regimens to improve outcomes. Our finding of a
trend toward better survival in patients who were diagnosed
and treated earlier in the course of disease, suggests that
further studies are also needed to learn how to best diagnose
and manage this expanding group of complex disorders prior
to transplant.
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